Equal-WT
WhaleScore 2.0
?
REDMILE GROUP, LLC
SAN FRANCISCO
Investment Advisor
Hedge Fund
Activist Investor
Redmile Group is based out of San Francisco. Redmile Group is a hedge fund with 26 clients and discretionary assets under management (AUM) of $4,835,026,495 (Form ADV from 2025-03-31). Their last reported 13F filing for Q1 2025 included $1,057,997,904 in managed 13F securities
and a top 10 holdings concentration of 61.75%. Redmile Group's largest holding is Scholar Rock Holding Corp with shares held of 4,398,281. Whalewisdom has at least 79 13F filings, 52 13D filings, 277 13G filings, and 155 Form 4 filings
Business Description
Redmile Group, LLC, formed in March 2007, provides investment management, advisory, and sub-advisory services to investment vehicles exempt from registration under the Investment Company Act. The Firm's advisory services are directed towards the Funds, under the guidance of each Fund's General Partner, rather than individual investors within the Funds. The Firm may also have affiliates that provide advisory services to and/or receive advisory fees from the Funds.
The Firm's business involves recommending services of a portfolio company to other portfolio companies of the Funds, which may involve fees, commissions, servicing payments and/or discounts to the Firm, an affiliate, or a portfolio company. This collaborative approach can create conflicts of interest, as the Firm has an incentive to maintain goodwill with portfolio companies, potentially influencing recommendations even if they aren't the best option for the Funds' portfolio companies.
Investment Strategy
The Firm employs various investment strategies on behalf of the Funds, utilizing different investment instruments, each carrying its own set of risks. These strategies are not uniformly applied across all Funds.
The Firm manages multiple Funds with similar investment objectives, and may establish new funds with similar or different objectives in the future. The Firm may advise or act on investments for one or more Funds differently than others with similar programs, leading to variations in securities held and performance. Funds may also differ in investment vehicles, credit access, and strategies, resulting in price, leverage, and cost variations for specific opportunities.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2025-03-31
Top Buys (13F)
| Name | % Change |
|---|---|
| FOLD Amicus Therapeutics | 2.72% |
| IRTC iRhythm Technologies | 0.56% |
| SLDB Solid Biosciences In | 0.53% |
| PODD Insulet Corporation | 0.5% |
| MASI Masimo Corp | 0.41% |
2025-03-31
Top Sells (13F)
| Name | % Change |
|---|---|
| PLRX Pliant Therapeutics, | 2.4% |
| NRIX Nurix Therapeutics, | 0.96% |
| SYK Stryker Corp | 0.77% |
| STOK Stoke Therapeutics I | 0.71% |
| NGNE Neurogene Inc | 0.65% |
2025-03-31
13F Holdings Summary
| Name | $ Change |
|---|---|
| SRRK Scholar Rock Holding | 13.37% |
| KRYS Krystal Biotech Inc | 12.57% |
| FOLD Amicus Therapeutics | 7.35% |
| ZYME Zymeworks Inc | 5.39% |
| NRIX Nurix Therapeutics, | 4.55% |
The attached information table excludes (a) 11,884 shares of common stock of IGM BIOSCIENCES INC issued pursuant to restricted stock unit awards and (b) 11,331 shares of common stock of FATE THERAPEUTICS INC issued pursuant to restricted stock unit awards.
2025-03-31
13F Activity
| Market Value | $1.06b, Prior: $1.43b |
| Inflows (Outflows) as % of Total MV | (-3.1892)% |
| New Purchases | 2 stocks |
| Added To | 7 stocks |
| Sold out of | 8 stocks |
| Reduced holdings in | 32 stocks |
| Top 10 Holdings % | 61.75% |
| Turnover %[1] | 15.63% |
| Turnover Alt %[2] | 4.52% |
| Time Held Top 20 | 7 quarters |
| Time Held Top 10 | 6.9 quarters |
| Time Held All | 14.73 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2025-03-31
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2025-03-31
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2025-03-31